Login to Your Account

Turning table on label, FDA fatty-meal new deal still no defeat, says Elite

By Randy Osborne
Staff Writer

Monday, July 18, 2016

The FDA switcheroo that's holding up Elite Pharmaceuticals Inc.'s Sequestox, the firm's abuse-deterrent opioid for pain "should not take that long" to resolve, CEO Nasrat Hakim said during a conference call.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription